ERBB2 and breast cancer: This finding is in accordance with recent population-based studies that observed longer disease-free survival (DFS) among patients with HR-positive disease compared to HR-negative disease, regardless of HER2 status (IHC0 or low), and thus suggest HR status to be an independent prognostic factor for DFS in patients with HER2- BC [31,32].